**Conclusion** Resolvin E3 could be a potential therapeutic target for the cancer treatment.

**IGCS20_1085**

**113** **DOEGE – POTTER SYNDROME: A RARE PRESENTATION OF PELVIC MALIGNANT SOLITARY FIBROUS TUMOUR**

R Sinha*, N Kiely, K Wan. The Royal Hospital for Women, Australia

10.1136/ijgc-2020-IGCS.97

**Introduction** Solitary fibrous tumours (SFTs) are a rare mesenchymal neoplasm with an incidence of 2.8 per 100,000. Only 1% are reported to occur in the female genital tract. Approximately 5–10% of SFTs are associated with Doege–Potter syndrome, a para-neoplastic phenomenon with non-islet cell hypoglycaemia due to tumour production of low molecular weight insulin growth-like factor (IGF) - II.

**Methods** We present the third reported case of a pelvic SFT with Doege–Potter syndrome in a 61 year-old woman who presented with an unwitnessed collapse at home and a BSL of 1.25 mg/dL. CT scan found a 23 cm right sided pelvic mass adjacent to the uterus. She underwent emergency surgery due to refractory hypoglycaemia. The mass was extremely vascular and resulted in an 8.3L blood loss requiring a massive transfusion, postoperative ICU admission and management of acute kidney injury and transfusion-related lung injury. Glycaemic control was achieved immediately upon tumour removal. Her recovery was uncomplicated and final histopathology confirmed SFT with malignant transformation. We present a literature review of the previous cases and discuss the challenges involved in diagnosis and treatment.

**Conclusion** Doege - Potter syndrome is an extremely rare presentation of pelvic SFT. Complete surgical excision is the gold standard for treatment of this rare condition.

**IGCS20_1086**

**114** **IDENTIFICATION OF FACTORS IMPACTING RECURRENCE IN PATIENTS TREATED FOR BORDERLINE OVARIAN TUMORS: A FOCUS ON RADICALITY AND MINIMALLY-INVASIVE APPROACH**

M Longo*, N Ottolina, A Lembo, M Dri, G La Motta, V Granato, F Ghezzi, J Casarin. Obstetrics and Gynecology Dpt. University of Insubria, Italy

10.1136/ijgc-2020-IGCS.98

**Introduction** To compare oncological outcomes and disease-free survival (DFS) of patients with borderline ovarian tumors (BOTs) treated via laparotomy (LPT) vs. laparoscopy (LPS) and to evaluate the impact of the different radicalities of treatment on DFS.